Cargando…
Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy
BACKGROUND: Larger infarct size measured by creatine kinase (CK)-MB release is associated with higher mortality and has been used as an important surrogate endpoint in the evaluation of new treatments for ST-segment elevation myocardial infarction (STEMI). Traditional approaches to quantify infarct...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3662641/ https://www.ncbi.nlm.nih.gov/pubmed/23782531 http://dx.doi.org/10.1186/1745-6215-14-123 |
_version_ | 1782270857593225216 |
---|---|
author | Lopes, Renato D Lokhnygina, Yuliya Hasselblad, Victor Newby, Kristin L Yow, Eric Granger, Christopher B Armstrong, Paul W Hochman, Judith S Mills, James S Ruzyllo, Witold Mahaffey, Kenneth W |
author_facet | Lopes, Renato D Lokhnygina, Yuliya Hasselblad, Victor Newby, Kristin L Yow, Eric Granger, Christopher B Armstrong, Paul W Hochman, Judith S Mills, James S Ruzyllo, Witold Mahaffey, Kenneth W |
author_sort | Lopes, Renato D |
collection | PubMed |
description | BACKGROUND: Larger infarct size measured by creatine kinase (CK)-MB release is associated with higher mortality and has been used as an important surrogate endpoint in the evaluation of new treatments for ST-segment elevation myocardial infarction (STEMI). Traditional approaches to quantify infarct size include the observed CK-MB peak and calculated CK-MB area under the curve (AUC). We evaluated alternative approaches to quantifying infarct size using CK-MB values, and the relationship between infarct size and clinical outcomes. METHODS: Of 1,850 STEMI patients treated with reperfusion therapy in the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) (percutaneous coronary intervention (PCI)-treated) and the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) (fibrinolytic-treated) trials, 1,718 (92.9%) (COMMA, n = 868; COMPLY, n = 850) had at least five of nine protocol-required CK-MB measures. In addition to traditional methods, curve-fitting techniques were used to determine CK-MB AUC and estimated peak CK-MB. Cox proportional hazards modeling assessed the univariable associations between infarct size and mortality, and the composite of death, heart failure, shock and stroke at 90 days. RESULTS: In COMPLY, CK-MB measures by all methods were significantly associated with higher mortality (hazard ratio range per 1,000 units increase: 1.09 to 1.13; hazard ratio range per 1 standard deviation increase: 1.41 to 1.62; P <0.01 for all analyses). In COMMA, the associations were similar but did not reach statistical significance. For the composite outcome of 90-day death, heart failure, shock and stroke, the associations with all CK-MB measures were statistically significant in both the COMMA and COMPLY trials. CONCLUSIONS: Sophisticated curve modeling is an alternative to infarct-size quantification in STEMI patients, but it provides information similar to that of more traditional methods. Future studies will determine whether the same conclusion applies in circumstances other than STEMI, or to studies with different frequencies and patterns of CK-MB data collection. |
format | Online Article Text |
id | pubmed-3662641 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-36626412013-06-05 Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy Lopes, Renato D Lokhnygina, Yuliya Hasselblad, Victor Newby, Kristin L Yow, Eric Granger, Christopher B Armstrong, Paul W Hochman, Judith S Mills, James S Ruzyllo, Witold Mahaffey, Kenneth W Trials Research BACKGROUND: Larger infarct size measured by creatine kinase (CK)-MB release is associated with higher mortality and has been used as an important surrogate endpoint in the evaluation of new treatments for ST-segment elevation myocardial infarction (STEMI). Traditional approaches to quantify infarct size include the observed CK-MB peak and calculated CK-MB area under the curve (AUC). We evaluated alternative approaches to quantifying infarct size using CK-MB values, and the relationship between infarct size and clinical outcomes. METHODS: Of 1,850 STEMI patients treated with reperfusion therapy in the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) (percutaneous coronary intervention (PCI)-treated) and the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) (fibrinolytic-treated) trials, 1,718 (92.9%) (COMMA, n = 868; COMPLY, n = 850) had at least five of nine protocol-required CK-MB measures. In addition to traditional methods, curve-fitting techniques were used to determine CK-MB AUC and estimated peak CK-MB. Cox proportional hazards modeling assessed the univariable associations between infarct size and mortality, and the composite of death, heart failure, shock and stroke at 90 days. RESULTS: In COMPLY, CK-MB measures by all methods were significantly associated with higher mortality (hazard ratio range per 1,000 units increase: 1.09 to 1.13; hazard ratio range per 1 standard deviation increase: 1.41 to 1.62; P <0.01 for all analyses). In COMMA, the associations were similar but did not reach statistical significance. For the composite outcome of 90-day death, heart failure, shock and stroke, the associations with all CK-MB measures were statistically significant in both the COMMA and COMPLY trials. CONCLUSIONS: Sophisticated curve modeling is an alternative to infarct-size quantification in STEMI patients, but it provides information similar to that of more traditional methods. Future studies will determine whether the same conclusion applies in circumstances other than STEMI, or to studies with different frequencies and patterns of CK-MB data collection. BioMed Central 2013-05-02 /pmc/articles/PMC3662641/ /pubmed/23782531 http://dx.doi.org/10.1186/1745-6215-14-123 Text en Copyright © 2013 Lopes et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Lopes, Renato D Lokhnygina, Yuliya Hasselblad, Victor Newby, Kristin L Yow, Eric Granger, Christopher B Armstrong, Paul W Hochman, Judith S Mills, James S Ruzyllo, Witold Mahaffey, Kenneth W Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy |
title | Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy |
title_full | Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy |
title_fullStr | Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy |
title_full_unstemmed | Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy |
title_short | Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy |
title_sort | methods of creatine kinase-mb analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3662641/ https://www.ncbi.nlm.nih.gov/pubmed/23782531 http://dx.doi.org/10.1186/1745-6215-14-123 |
work_keys_str_mv | AT lopesrenatod methodsofcreatinekinasembanalysistopredictmortalityinpatientswithmyocardialinfarctiontreatedwithreperfusiontherapy AT lokhnyginayuliya methodsofcreatinekinasembanalysistopredictmortalityinpatientswithmyocardialinfarctiontreatedwithreperfusiontherapy AT hasselbladvictor methodsofcreatinekinasembanalysistopredictmortalityinpatientswithmyocardialinfarctiontreatedwithreperfusiontherapy AT newbykristinl methodsofcreatinekinasembanalysistopredictmortalityinpatientswithmyocardialinfarctiontreatedwithreperfusiontherapy AT yoweric methodsofcreatinekinasembanalysistopredictmortalityinpatientswithmyocardialinfarctiontreatedwithreperfusiontherapy AT grangerchristopherb methodsofcreatinekinasembanalysistopredictmortalityinpatientswithmyocardialinfarctiontreatedwithreperfusiontherapy AT armstrongpaulw methodsofcreatinekinasembanalysistopredictmortalityinpatientswithmyocardialinfarctiontreatedwithreperfusiontherapy AT hochmanjudiths methodsofcreatinekinasembanalysistopredictmortalityinpatientswithmyocardialinfarctiontreatedwithreperfusiontherapy AT millsjamess methodsofcreatinekinasembanalysistopredictmortalityinpatientswithmyocardialinfarctiontreatedwithreperfusiontherapy AT ruzyllowitold methodsofcreatinekinasembanalysistopredictmortalityinpatientswithmyocardialinfarctiontreatedwithreperfusiontherapy AT mahaffeykennethw methodsofcreatinekinasembanalysistopredictmortalityinpatientswithmyocardialinfarctiontreatedwithreperfusiontherapy |